Physician profile
Michael Ruder
NPI 1679506208
$871.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $254.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $148.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $93.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $77.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.78 | 2019-2020 | |
| Abbott Laboratories | $60.32 | 2020 | |
| Pfizer INC. | $35.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.87 | 2020 | |
| Lundbeck LLC | $24.36 | 2019 | |
| Novo Nordisk INC | $19.84 | 2019 | |
| Daiichi Sankyo INC. | $19.42 | 2019 | |
| Boston Scientific Corporation | $14.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ruder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.